Mistral Pharma Inc.
TSX VENTURE : MIP

Mistral Pharma Inc.

September 20, 2005 10:04 ET

Mistral Pharma Reports Positive Results From Pilot Clinical Trial of First Branded Product: MIST-B01

MONTREAL, QUEBEC--(CCNMatthews - Sept. 20, 2005) - Mistral Pharma Inc. (TSX VENTURE:MIP) announced today that the pilot clinical trial of the branded product MIST-B01 showed positive results. The MIST-B01 once-daily formulation meets the study objectives relative to area under the curve (AUC) and maximum concentration (Cmax) resulting in a very nice 24h pharmacokinetic profile compared to the reference product taken twice daily.

"We are very pleased with these results and will be seeking a commercial partner for MIST-B01 right away" said Bertrand Bolduc, President & CEO of Mistral Pharma. "MIST-B01 is not only a very interesting commercial opportunity for a specialty pharma but also represents an advantageous once-daily therapeutic alternative for patients" commented Mr. Bolduc.

MIST-B01, Mistral's first branded product, is a controlled-delivery formulation of a widely prescribed drug, which is already approved around the world for numerous indications. According to Drug Topics, the total generic sales for this drug are approximately US $300 M.

About Mistral Pharma Inc.

Mistral Pharma is an emerging oral drug delivery company which develops generic and branded controlled-delivery products using its PROCISE™, SAVIT™ and CHRONOP™ geometry surface area technologies. These technologies offer many competitive advantages including flexible and fast development, competitive cost of goods and the use of "generally recognized as safe" excipients. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information